Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spread Of H5N1 Bird Flu Virus Genetically Traced To Southern China

This article was originally published in PharmAsia News

Executive Summary

Researchers studying the genetic makeup of the H5N1 avian influenza virus have located the likely source of it to the Yunnan and Hunan provinces in Southern China. The strains detected in Malaysia, Thailand and Vietnam in 2002, 2003 resembled the Yunnan Province strain, they said, while the Indonesia outbreak was related to strains in Hunan during the same period. According to the scientists in a published report, poultry trade may be responsible for the strain getting to Vietnam, but a direct link from Hunan to Indonesia was not established. (Click here for more

You may also be interested in...

Sinovac’s Panflu Is First Chinese Avian Flu Vaccine Approved By SFDA

SHANGHAI - Sinovac Biotech has been granted a production license for its pandemic influenza vaccine Panflu from China's State FDA, the company announced April 2. Panflu is the first vaccine approved since SFDA implemented its Special Drug Approval Procedures in 2005

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts